ResearcherNingbo UniversityActive in the last 2 years

Kaiwei Xu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5125590168. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 2 papers

Papers 2

Dual-pathway blockade overcomes ferroptosis resistance in pancreatic ductal adenocarcinoma via a CD133-targeted manganese-porphyrin theranostic nanoplatform. Co-author DOI 10.1016/j.biomaterials.2026.124340 ↗
Ultrasmall Iron Oxide as an Imaging Nanoenzyme Loaded Autologous Exosomes for Targeted Imaging and Chemotherapy Promotion of Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.5c01556 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ruoyu Wu · 1 shared paper, 2026 · strength 0.30
- Paper Ultrasmall Iron Oxide as an Imaging Nanoenzyme Loaded Autologous Exosomes for Targeted Imaging and Chemotherapy Promoti… DOI 10.1021/acs.molpharmaceut.5c01556 ↗
Jianhua Wang · 1 shared paper, 2026 · strength 0.30
- Paper Ultrasmall Iron Oxide as an Imaging Nanoenzyme Loaded Autologous Exosomes for Targeted Imaging and Chemotherapy Promoti… DOI 10.1021/acs.molpharmaceut.5c01556 ↗
Lufei Jin · 1 shared paper, 2026 · strength 0.30
- Paper Ultrasmall Iron Oxide as an Imaging Nanoenzyme Loaded Autologous Exosomes for Targeted Imaging and Chemotherapy Promoti… DOI 10.1021/acs.molpharmaceut.5c01556 ↗
Jianhua Wang · 1 shared paper, 2026 · strength 0.27
- Paper Dual-pathway blockade overcomes ferroptosis resistance in pancreatic ductal adenocarcinoma via a CD133-targeted mangane… DOI 10.1016/j.biomaterials.2026.124340 ↗
Aiguo Wu · 1 shared paper, 2026 · strength 0.27
- Paper Dual-pathway blockade overcomes ferroptosis resistance in pancreatic ductal adenocarcinoma via a CD133-targeted mangane… DOI 10.1016/j.biomaterials.2026.124340 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.